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Introduction
Inappropriate or persistent neutrophilic inflammation is implicat-
ed in a number of disease states exemplified by acute lung injury 
responses and chronic obstructive pulmonary disease. There are, 
to date, no effective therapeutic strategies for targeting neutrophil-
ic inflammation, a reflection in part of the fine balance that exists 
between maintaining effective host pathogen responses and lim-
iting host-mediated tissue damage. Local and systemic hypoxia 
represent a critical component of the inflammatory response, with 
oxygen-sensing pathways implicated in the regulation of neutro-
phil survival. The coordination of cellular responses to differing 
oxygen tensions is tightly controlled and involves hydroxylation 
of the HIF subunits, with prolyl hydroxylation targeting HIFs for 
ubiquitylation and proteosomal degradation (1, 2). In humans, 3 
prolyl hydroxylase enzymes are described (PHD1–3), with PHD2 
the most abundant isoform and important in setting basal levels of 
HIF-1α in the majority of cells cultured in normoxia (3–6). While 
there is emerging evidence that genetically observed PHD2 varia-
tions result in distinct clinical phenotypes (7–9), the overall physio-
logical roles of PHD2 are only now emerging. An important exam-
ple is the critical role of PHD2 in macrophage polarization, with 
haplodeficiency of Phd2 resulting in expansion of tissue-resident 
M2 macrophages with consequences for arteriogenesis (10).
We have previously observed that neutrophils express all 3 
PHDs. PHD2 is both expressed constitutively and upregulated in 
sterile inflammation, where PHD2 expression follows HIF activi-
ty. In marked contrast to PHD3 expression, however, only modest 
changes in PHD2 transcript are observed in response to hypoxic 
cell culture (11). HIF-1α, HIF-2α, and PHD3 have all been shown 
to regulate neutrophil survival and function, with implications for 
neutrophilic inflammation (11–13). In vivo inactivation of both Hif1α 
and Phd3 results in abolished hypoxic survival and loss of function-
al capacity. Inactivation of Hif2α is also associated with a reduction 
in neutrophilic inflammation and tissue damage, as a consequence 
of increased neutrophil apoptosis. This suggests PHD2 is likely to 
also play a role in mechanisms regulating neutrophil apoptosis. 
Conceptually, it is also likely that individual PHD family members 
play distinct roles in regulating key neutrophil functional and sur-
vival responses under differing oxygen tensions (11, 12, 14).
An increasing body of work has focused on the potential roles 
of prolyl hydroxylases as metabolic sensors, in addition to their 
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1D) in blood and correlated with enhanced levels of the neutro-
phil chemokines KC and MIP-1B (Supplemental Figure 2, A–D). 
In keeping with a neutrophil-intrinsic response, Phd2-deficient 
airway neutrophils expressed higher levels of CXCR2 and CD11a 
(Figure 1, G and H), with no effect of Phd2 loss on BMDM cytokine 
expression (Supplemental Figure 2, E–H), as previously reported 
(26). Importantly, maximal neutrophil recruitment reached equiv-
alence between genotypes at 24 hours, suggesting Phd2–/– mice 
had more rapid neutrophil recruitment rather than recruiting 
greater cell numbers (Figure 1I). In keeping with the phenotype 
observed following pulmonary infection with S. pneumoniae, we 
found delayed inflammation resolution (Figure 1J) and neutrophil 
persistence (Figure 1, K and L) in Phd2–/– animals and a significant 
reduction in detectable neutrophil apoptosis (Figure 1M), with a 
parallel increase in BAL IgM release (Figure 1N). In a model of 
more chronic inflammation, dextran sulfate sodium (DSS) diet–
induced colitis, greater neutrophil persistence was seen in het-
erozygous Phd2+/– than in WT mice (Figure 1O). Taken together, 
these data implicate Phd2 in both the recruitment and resolution 
of neutrophil-mediated inflammatory responses, with potentially 
important consequences for resultant tissue damage.
Phd2-deficient neutrophils display enhanced function and sur-
vival ex vivo. The importance of Phd2 expression in regulating key 
inflammatory neutrophil functions was investigated ex vivo in neu-
trophils recruited to the airways at 24 hours following in vivo chal-
lenge with LPS. Freshly isolated BAL neutrophils lacking Phd2 dis-
played increased basal motility in the chemokinesis control (Kc/Kc) 
and enhanced chemotaxis to the murine IL-8 homologue KC at the 
point of isolation (Figure 2A). Ex vivo stimulation with the N-formy-
lated bacterial chemotactic peptide N-formylmethionyl-leucyl- 
phenylalanine (fMLP) was unable to induce an increase in respira-
tory burst activity in either genotype (Figure 2B), and no difference 
in inner mitochondrial membrane potential was seen (Figure 2C). 
Following aging for an additional 6 hours, to investigate the func-
tional reserve capacity of the inflammatory cells, the differences in 
chemotactic behavior were measured and were even more apparent 
(Figure 2D), while respiratory burst (Figure 2E) and inner mitochon-
drial membrane potential (Figure 2F) remained unchanged, despite 
a detectable increase in mitochondrial ROS production measured 
by MitoSOX (Figure 2G). In keeping with the equivalent lung CFU 
counts observed in vivo (Figure 1D) and in contrast with BMDMs 
(Supplemental Figure 3A), Phd2-deficient neutrophils demonstrat-
ed equivalent bacterial phagocytic capacity ex vivo (Figure 2H). At 
both an early (Figure 2I) and late (Figure 2J) time point, peripheral 
blood neutrophils from Phd2–/– animals displayed reduced constitu-
tive rates of apoptosis and preserved survival responses to both LPS 
(Figure 2I) and hypoxic culture (WT 34.5% ± 7.39%, Phd2–/– 18.0% ± 
3.74% apoptotic) (Figure 2J), in keeping with the observed differenc-
es in apoptosis rates in vivo (Figure 1L). There was no effect of Phd2 
loss on macrophage efferocytosis (Supplemental Figure 3B). Thus, 
neutrophils show both increased activation and increased longevi-
ty in the absence of Phd2. The further augmentation of Phd2-defi-
cient neutrophil survival by hypoxia implies both PHD2-dependent 
and -independent regulation of neutrophil apoptosis responses. To 
address the neutrophil specificity of the phenotype in vivo, we chal-
lenged Phd2fl/fl LysM-Cre positive and negative mice with LPS and 
with serotype 2 (D39) S. pneumoniae following alveolar macrophage 
role as oxygen sensors, both indirectly through their regulation of 
HIF-mediated signaling and directly through their dependence 
on the tricarboxylic acid (TCA) cycle intermediate α-ketogluta-
rate (α-KG) and their ability to interact with the glycolytic enzyme 
pharmacokinetics (PK) (1, 15–20). This linking of metabolism to 
cell survival and function has important implications for the role 
of PHD enzymes in regulating myeloid cell functional responses, 
particularly in light of recent macrophage studies linking meta-
bolic status to macrophage polarization and immune signaling 
(21–23). In neutrophils, we observed that mutations in succinate 
dehydrogenase B result in enhanced neutrophil survival respons-
es, despite evidence of a dysfunctional TCA cycle (24), directly 
linking metabolism with neutrophil survival. The importance of 
changes in the metabolic capacity of neutrophils and, more specif-
ically, flux between individual metabolic pathways under resting 
and activated states remains to be fully explored, as does the role 
PHD enzymes may play in coordinating these responses.
In this work, we address the consequences of myeloid- 
specific loss of Phd2 for host-pathogen interactions and link the 
metabolic state of neutrophils to survival and functional status. 
Our findings reveal that loss of Phd2 results in increases in neu-
trophil activation and persistence, resulting in increased tissue 
injury following challenge with intratracheal Streptococcus pneu-
monia. We demonstrate that enhanced survival and function of 
Phd2-deficient neutrophils is directly linked to their metabolic 
capacity and that modulating neutrophil metabolism can alter 
outcomes of infection and inflammation.
Results
Myeloid-specific deletion of Phd2 results in enhanced neutrophilic 
inflammation and lung injury. To investigate the consequences 
of Phd2 loss for host pathogen responses, we challenged Phd2fl/fl 
LysM-Cre positive and negative (hereafter myeloid-specific Phd2–/– 
and WT, respectively) littermate controls with serotype 4 S. pneu-
moniae (TIGR4) in a model of fulminant bacterial pneumonia with 
associated secondary bacteremia. Loss of Phd2, verified in neutro-
phil and bone marrow–derived macrophage (BMDM) populations 
by real-time PCR (Supplemental Figure 1, A and B; supplemental 
material available online with this article; https://doi.org/10.1172/
JCI90848DS1), resulted in higher total (Figure 1A) and neutrophil 
(Figure 1B) bronchoalveolar lavage (BAL) cell counts, with a corre-
sponding increase in levels of BAL IgM, a marker of vascular injury 
(Figure 1C). The bacterial burden was unchanged both regionally 
in the lung (Figure 1D) and in the circulation (Figure 1E). Given the 
augmented inflammatory response observed following challenge 
with a live bacterial pathogen, in which both early macrophage 
and subsequent neutrophil responses are required for effective 
pathogen clearance (25), we proceeded to define the importance 
of myeloid-specific expression of Phd2 in another murine model of 
acute lung injury that is more specifically mediated by neutrophils. 
Following intratracheal challenge of mice with bacterial lipopoly-
saccharide (LPS) during the early phase of neutrophil recruit-
ment (6 hours after LPS), myeloid-specific Phd2–/– mice displayed 
increased lavage total cell counts, largely reflecting increased neu-
trophil numbers (Figure 1F). This was associated with a normal 
Phd2–/– baseline (Supplemental Figure 1C) and LPS-stimulated 
total white cell and differential cell counts (Supplemental Figure 
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MRP8-Cre+/– mice displayed increased total BAL cell counts and 
BAL neutrophil numbers when compared with WT mice at 48 hours 
after LPS challenge (Figure 2K).
Inflammatory neutrophils deficient in Phd2 display enhanced gly-
colytic capacity with parallel increases in both ATP and intracellular 
glycogen stores. To investigate whether Phd2-deficient phenotypes 
could be, at least in part, due to compensatory overexpression of 
genes encoding for other PHD family members, relative quantifi-
cation of Phd mRNA was undertaken on freshly isolated BAL neu-
trophils 24 hours after LPS challenge. No differences in expression 
of either Phd1 or Phd3 were observed at an mRNA level (Figure 3A). 
depletion with clodronate (Supplemental Figure 3C). In response to 
LPS, Phd2-deficient animals again demonstrated elevated 6-hour 
airway neutrophil counts (Supplemental Figure 3, D and E), equiva-
lent maximal neutrophil recruitment (Supplemental Figure 3, F and 
G), and enhanced persistence (Supplemental Figure 3, H and I). Fol-
lowing S. pneumoniae challenge, there were again increased airway 
leukocyte counts (Supplemental Figure 3, J and K), despite equiv-
alent bacterial burden (Supplemental Figure 3L). To more directly 
address the consequence of neutrophil deletion of Phd2, we crossed 
Phd2fl/fl animals with the previously reported neutrophil-specific 
Cre driver MRP8 (27) (Supplemental Figure 3, M and N). Phd2fl/fl 
Figure 1. Myeloid-specific Phd2 deficiency results in aberrant neutrophilic inflammation. WT (white bars) and myeloid-specific Phd2–/– (black bars) mice 
were studied in parallel. (A–E) Mice were infected via the trachea with 1 × 107 CFU of TIGR4. Cells were harvested by BAL at 14 hours and total cell counts 
(A) and neutrophil differential counts (B) obtained. Total IgM release into bronchoalveolar fluid (C) and viable bacterial counts recovered from homoge-
nized lung (D) or whole blood (E) were performed in parallel (n = 15). (F–L) Acute lung injury. Intratracheal LPS (0.3 mg) was instilled in anesthetized mice. 
Mice were sacrificed at 6 hours after challenge and cells harvested by BAL for total cell counts (F) and surface expression of CXCR2 (G) and CDlla (H). At 
24 (I), 48, and 72 hours (J–N) after challenge, cells/supernatants were harvested by BAL for total cell counts (I, J, L), neutrophil differential counts (I, K, L), 
morphological counts of apoptosis (M), and measures of total IgM release (N) (n = 7). (O) DSS colitis. Six days following DSS diet–induced colitis, colonic 
sections were harvested, paraffin-fixed, and anti-MPO antibody stained. ALI, acute lung injury. P values obtained via unpaired t test.
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Figure 2. Phd2-deficient neutrophils display augmented inflammatory responses. (A–G) Murine inflammatory BAL neutrophils were isolated from WT 
(white bars) and myeloid-specific Phd2–/– (black bars) mice 24 hours after in vivo LPS (3 mg) challenge and studied either at point of isolation (A–C) or 
following aging in culture for 6 hours (D–G). (A and D) Chemotaxis. Chemotaxis to KC (100 nM) was determined using neuroprobe chambers. (B and E). 
Respiratory burst. Change in DCF emission, an indicator of cellular oxidative stress, was quantified by flow following 30 minutes stimulation with fMLP 
(10 μM). (C and F) Inner mitochondrial membrane potential. FL2 geometric mean fluorescence with tetramethylrhodamine, methyl ester (TMRM) uptake 
was quantified by flow cytometry in the presence or absence of CCCP (10 μM). CCCP was used as a negative control for the TMRM measure of inner mito-
chondrial membrane potential and works by collapsing the proton gradient. TMRM is a cell-permeant cationic fluorescent dye that accumulates in active 
mitochondria and is distributed throughout the cytosol when mitochondrial membrane potential collapses. (G) Mitochondrial ROS. MitoSOX fluorescent 
emission was quantified by flow cytometry in the presence or absence of CCCP (10 μM). (H) Inflammatory BAL neutrophil bacterial phagocytosis. Alexa 
Fluor 488–conjugated E. coli BioParticles (MOI 5:1) were administered to inflammatory BAL neutrophil for 1 hour. (I and J) Apoptosis. Peripheral blood neu-
trophils were isolated from WT (white bars) and knockout Phd2–/– (black bars) mice and cultured in the presence/absence of LPS (100 ng/ml) in normoxia 
(19 kPa, 21% O2) or hypoxia (3 kPa, 3% O2) for 5 (I) or 9 (J) hours and apoptosis assessed by morphology. (K) Phd2fl/fl MRP8-Cre+/– (MRP8;Phd2fl/fl) and WT 
control mice were nebulized with LPS (3 mg) and cells harvested by BAL for total cell counts and neutrophil differential counts. Data represent mean ± 
SEM, n = 4. MFI, mean fluorescence intensity. P values obtained via 2-way ANOVA (A, D, I, J) and unpaired t test (G and K).
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HIF-1α protein in Phd2–/– mice (Figure 3C). In light of the observed 
increase in glycolytic enzymes, we questioned whether Phd2-defi-
cient neutrophils would display either a basal increase in glycolysis 
or an exaggerated metabolic response to proinflammatory media-
No changes in either Hif1a or Hif2a mRNA were observed (Figure 
3A), but key regulators of glycolysis and known HIF target genes 
Pkm2, Pgk, Tpi1, and Gapdh were increased (Figure 3B), with a par-
allel and sustained increase in tissue myeloid cell expression of 
Figure 3. Phd2-deficient inflammatory neutrophils display increased HIF-1α expression and activity and enhanced glycolytic capacity. (A and B) Murine 
inflammatory BAL neutrophils were studied following isolation 24 hours after in vivo challenge with nebulized LPS (3 mg). WT (white bars) and myeloid- 
specific Phd2–/– (black bars) neutrophils were lysed and TaqMan analysis of cDNA performed with data normalized to β-actin expression. (C) Acute lung injury. 
Mice were challenged with nebulized LPS (3 mg) and sacrificed at 6, 24, and 48 hours. Lungs were fixed with 10% buffered formalin and paraffin embedded. 
Sections were stained for expression of HIF-1α. Original magnification, ×400. (D–F) Glycolytic capacity. Bone marrow (D) and inflammatory BAL (E) neutrophils 
were isolated from WT (white bars) and myeloid-specific Phd2–/– (black bars) mice. ECARs were determined by Seahorse (D) and glycolytic flux by quantifica-
tion of 3H2O release following uptake of 5-
3H glucose (E) in the presence or absence of glucose (1 mg/ml), fMLP (10 μM), and LPS (100 ng/ml) under conditions 
of normoxia (N, 21% O2) and hypoxia (H, 3% O2). (F) Box plot analysis of the relative change in glycolytic intermediary abundances measured by LC-MS in 
inflammatory BAL neutrophils from WT and myeloid-specific Phd2–/– mice following 6 hours culture under conditions of normoxia (N, 21% O2) and hypoxia  
(H, 3% O2). Data represent mean with minimum to maximum values, n = 3. Overall significance between genotypes for relative analyte abundance was deter-
mined by 2-way ANOVA, P < 0.5 for WT normoxia (dashed line) vs. Phd2 normoxia. P values obtained via unpaired t test (B and E) and 2-way ANOVA (D and F).
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tors. Extracellular acidification rates (ECAR), an indirect measure 
of glycolysis (28), were initially determined for WT cells, comparing 
bone marrow isolated neutrophils (Supplemental Figure 4A) with 
BAL neutrophils (Supplemental Figure 4B). Both immature and 
inflammatory neutrophil populations displayed detectable baseline 
ECAR, which could be further increased by supplementation with 
glucose or stimulation with the chemotactic peptide fMLP (Figure 
3D). Baseline glycolytic flux was subsequently determined by mea-
sure of 3H2O release following uptake of 5-3H glucose in the pres-
ence or absence of LPS (Supplemental Figure 4C). Conditional loss 
of Phd2 resulted in a significant increase in bone marrow neutrophil 
ECAR following stimulation with glucose (Figure 3D) and in BAL 
neutrophil glycolytic flux (Figure 3E). Analysis of glycolytic inter-
mediaries carried out by liquid chromatography–mass spectrome-
try (LC-MS) verified the global increase in glycolytic metabolites in 
the absence of Phd2 in normoxia, with augmentation of metabolite 
fold change following exposure of Phd2-deficient BAL neutrophils 
to hypoxia (Figure 3F). In keeping with enhanced availability of 
glycolytic intermediaries, increased abundance of pentose phos-
phate pathway metabolites was also seen (Supplemental Figure 
4D). Inhibition of the pentose phosphate pathway in untreated and 
LPS-stimulated WT BAL neutrophils using the NADP+-dependent 
enzyme 6-phosphogluconate dehydrogenase inhibitor 6-amino-
nicotinamide (6-AN) had no observed effect on neutrophil apopto-
sis (Supplemental Figure 4E). To investigate whether the increase in 
glycolytic intermediaries was a consequence of increased glucose 
uptake or altered metabolic processing of glucose, BAL neutrophils 
were cultured with uniformly labeled U-13C glucose, in which all 
carbons of a glucose molecule are substituted with a 13C isotope 
(29). This revealed an increase in glucose label redistribution in 
Phd2-deficient BAL neutrophils under conditions of both normox-
ia and hypoxia. While the increase in total glucose-6-phosphate 
(G6P) was in keeping with increased glucose uptake (Figure 4A), 
the presence of multiple G6P isotopomers (m1–m6) (Figure 4A, 
relative abundance shown in Supplemental Figure 5) demonstrated 
a measure of conversion of nonglucose substrates into glucose in 
Phd2-deficient BAL neutrophils, an observation further validated 
by a parallel increase in intracellular glycogen stores (Figure 4B). 
This functional increase in glucose uptake occurred in the context 
of unchanged Glut1 (Supplemental Figure 6A) and Glut3 (Supple-
mental Figure 6B) mRNA expression. The global consequences of 
enhanced glycolytic flux and glycogen stores for neutrophil ener-
getics, ATP production, and utilization were therefore determined. 
Compared with WT cells, Phd2-deficient neutrophils contained 
higher relative levels of ATP (Figure 4C) and equivalent levels of 
ADP (Figure 4D) and AMP (Figure 4E), reflecting increased nucle-
otide production, with an overall increase in cellular energy charge 
also observed (Figure 4F).
Inhibition of glycolysis and glucose availability rescues the 
enhanced neutrophilic responses observed in myeloid-specific Phd2–/– 
mice. Clinically useful strategies for selectively targeting neutro-
phil-mediated inflammatory responses are currently lacking. We 
hypothesized that the uplift in glycolytic capacity seen in Phd2- 
deficient neutrophils was directly responsible, or at least critical 
for, the exaggerated neutrophil responses seen following chal-
lenge with live bacteria or bacterial products and thus represents 
a therapeutic target. Mice were initially challenged with intratra-
cheal LPS for 24 hours prior to i.p. administration of the glycolytic 
inhibitor 2 deoxy-d-glucose (2DG). The dosing regimen for 2DG 
was validated by the observed suppression of bone marrow neutro-
phil ECAR by in vivo treatment with 2DG (Figure 5A), and the con-
sequences for neutrophil apoptosis and inflammation resolution 
were then determined. The enhanced survival of peripheral blood 
neutrophils lacking Phd2 expression was completely reversed by 
treatment with 2DG (Figure 5B). Moreover, in vivo administration 
of 2DG abrogated the persistent increase in BAL total cell counts 
(Figure 5C) and neutrophil differential counts (Figure 5D). BAL 
neutrophils isolated from mice treated with 2DG also revealed 
a reduction in their chemotactic capacity to KC (Figure 5E). To 
assess whether neutrophils have the capacity to utilize glycogen 
for survival responses, we first questioned whether they express 
glycogen synthase, the key enzyme required for glycogen synthe-
sis. Relative quantification of Gys1 mRNA was undertaken on bone 
marrow neutrophils and revealed expression of the transcript in 
both WT and Phd2–/– cells (Figure 5F). In vitro, inhibition of gly-
cogen breakdown in Phd2-deficient inflammatory BAL neutro-
phils with CP-91149 (a glycogen phosphorylase inhibitor) resulted 
in significantly increased apoptosis rates (Figure 5G). Together, 
these data support the concept that changes in the metabolic sta-
tus of neutrophils critically regulate their function and survival. To 
investigate the importance of glycolytic capacity for inflammation 
resolution in the context of hypoxia, human peripheral blood neu-
trophils were cultured ex vivo and apoptosis determined both in 
deplete culture conditions and with the glycolytic inhibitor 2DG. 
Hypoxic survival was abrogated by the absence of glucose (Figure 
6A) and by glycolytic inhibition (Figure 6B). In vivo treatment with 
2DG during the resolution phase of the inflammatory response 
resulted in rescue of the persistent inflammation seen in the pres-
ence of hypoxia (Figure 6, C–E, G) with return of neutrophil apop-
tosis rates to normoxic levels (Figure 6F).
Pan hydroxylase inhibition replicates the Phd2-deficient pheno-
type in vivo. In order to investigate the consequences of in vivo 
Figure 4. Inflammatory neutrophils deficient in Phd2 display enhanced 
glycolytic capacity and glycogen storage with parallel increases in ATP 
production and utilization. Murine inflammatory BAL neutrophils from 
WT (white bars) and Phd2–/– (black bars) mice were studied following iso-
lation 24 hours after in vivo challenge with nebulized LPS (3 mg). (A) Glyco-
lytic metabolites. Murine inflammatory BAL neutrophils were cultured 
in the presence of U-13C glucose for 6 hours under conditions of normoxia 
(21% O2) and hypoxia (3% O2). Incorporation into G6P and redistribution of 
13C carbons derived from U-13C glucose were measured using LC-MS. Data 
are presented as relative metabolite abundance and show mean ± SEM,  
n = 3. A diagram of the glycolytic and gluconeogenesis pathways depicting 
2 possible outcomes resulting in the generation of G6P m3 isotopomer 
by recycling of 13C carbons is included. Total G6P is a measure of both 
unlabeled 12C G6P and all other mass isotopomers of G6P denoted m0–m6, 
where m0 contains only 12C carbons and m6 with all 6 carbons 13C. (B) Gly-
cogen content. WT (white bars) and myeloid-specific Phd2–/– (black bars) 
inflammatory BAL neutrophils were lysed at time of isolation and follow-
ing 6 hours culture in normoxia or hypoxia and intracellular glycogen stores 
quantified by a colorimetric assay. Data represent mean ± SEM, n = 5. (C–F) 
Energetics. BAL neutrophils were cultured for 6 hours ex vivo and relative 
ATP (C), ADP (D), and AMP (E) levels determined by LC-MS, enabling 
calculation of energy charge (F). Data represent mean ± SEM, n = 3. DHAP, 
dihydroxyacetone phosphate. P values obtained via unpaired t test.
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Discussion
A tightly coordinated innate immune response is critical for effec-
tive pathogen clearance with limited collateral tissue damage. 
There is a clinical need for therapies that selectively target exces-
sive or inappropriate inflammation while maintaining effective 
antimicrobial host responses. In this work, we identify an import-
ant role for PHD2 in the regulation of neutrophilic inflammation. 
We observe that myeloid-specific loss of Phd2 results in a disor-
dered inflammatory response that is detrimental to the host and 
imparts no measured benefit for bacterial killing or clearance. In 
marked contrast to the HIF-independent phenotype of abrogated 
hypoxic survival in Phd3-deficient neutrophils (11), loss of Phd2 
results in a delay in both neutrophil apoptosis and inflammation 
resolution. In parallel with enhanced neutrophil survival, we also 
observed an intrinsic neutrophil phenotype of augmented recruit-
ment, enhanced chemotaxis, and an increase in the functional 
reserve capacity of aged neutrophils. Given neutrophil migration is 
a highly energy-requiring process (33), that neutrophils are unusu-
administration of the potent HIF-prolyl hydroxylase inhibitor 
molidustat (30, 31) for inflammation resolution, molidustat was 
administered in vivo by gavage 2 hours (T–2) prior to challenge 
with nebulized LPS (3 mg) (T0). Molidustat is an example of a 
family of triacyclic triazole–based PHD inhibitors, which com-
pete with 2-oxoglutarate for binding with the ferrous iron at the 
active site of the PHDs (32). Molidustat increased both circulat-
ing reticulocyte (Figure 7A) and packed cell volume (Figure 7B), 
confirming expected actions at the concentration used, but did 
not significantly modify the number of neutrophils recruited to 
the lung following LPS challenge (Figure 7C) despite an increase 
in basal motility (Figure 7D). However, molidustat significantly 
delayed inflammation resolution, with an increase in total BAL 
cells (Figure 7E) reflecting an increase in the number of neu-
trophils persisting at 48 hours (Figure 7F). In addition, in vivo 
administration of molidustat resulted in an increase in baseline 
bone marrow neutrophil ECAR (Figure 7G) and significantly 
increased ATP levels in BAL neutrophils (Figure 7H).
Figure 5. Enhanced neutrophilic inflammation 
in myeloid-specific Phd2–/– mice is rescued by 
inhibition of glycolysis and glucose availability. (A) 
Validation of 2DG. WT (white bars) and myeloid-spe-
cific Phd2–/– (black bars) mice were challenged with 
nebulized LPS (3 mg) and, 24 hours after challenge, 
further treated with either i.p. 2DG (500 mg/kg) or 
PBS control. Forty-eight hours after LPS challenge, 
mice were sacrificed and bone marrow neutrophils 
harvested for Seahorse quantification of ECARs, with 
additional fMLP stimulation ex vivo. (B) Apoptosis. 
Peripheral blood neutrophils were isolated from 
WT (white bars) and myeloid-specific Phd2–/– (black 
bars) mice and apoptosis rates assessed at 5 hours 
in the presence or absence of 2DG (100 μM). (C) In 
vivo inflammation resolution. WT (white bars) and 
Phd2–/– cre+ (black bars) mice were challenged with 
nebulized LPS (3 mg) and 24 hours after challenge 
further treated with either i.p. 2DG (500 mg/kg) or 
PBS control. Forty-eight hours after LPS challenge, 
mice were sacrificed and cells harvested by BAL for 
total cell counts (C) and neutrophil differential counts 
(D). Data represent mean ± SEM, n = 5. (E) WT mice 
were challenged with nebulized LPS (T0) (3 mg), and 
i.p. installation with 2DG (500 mg/kg) or PBS vehicle 
control was carried out at T10. Mice were sacrificed at 
24 hours (T24) and cells harvested by BAL. Chemotaxis 
of the freshly isolated BAL neutrophils to KC was 
determined ex vivo using neuroprobe chambers. Data 
represent mean ± SEM, n = 6. (F) Glycogen synthase 
1 (Gys1) expression in bone marrow neutrophils. 
FACS-sorted bone marrow neutrophils of LPS- 
nebulized WT and Phd2-deficient mice were lysed 
and TaqMan analysis of cDNA performed with data 
normalized to β-actin expression. Data represent 
mean ± SEM, n = 4. (G) Phd2-deficient inflammatory 
BAL neutrophils were incubated for 20 hours in the 
presence or absence (Unt) of DMSO vehicle control or 
the glycogen phosphorylase inhibitor CP-91149. Effects 
on neutrophil apoptosis were assessed by morphology. 
Data represent mean ± SEM (n = 4). P values obtained 
via unpaired t test (A–E) and 1-way ANOVA (G).
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ble of the conversion of nonglucose substrates into glucose. This 
has particular relevance to the in vivo state, and inflamed sites in 
particular, given the limited glucose availability. While previous 
electron microscopy (EM) studies have detailed the presence of 
glycogen bodies within quiescent neutrophils (36, 37), our work 
provides direct evidence for regulation of neutrophil apoptosis 
through glycogen availability. The wider implications of the abil-
ity of neutrophils to maintain intracellular glucose and glycogen 
stores also require consideration, given the previous descriptions 
of neutrophil dysfunction in association with G6PT deficiency in 
humans (38) and G6Pase-b inactivation in mice (39). Furthermore, 
this leads us to speculate that neutrophils can themselves undergo 
gluconeogenesis and that PHD2 is an important regulator of this 
process. It is of particular interest, given the recent observation 
that both liver-specific knockdown of Phd2 and oral administra-
tion of a nonisoform-selective PHD inhibitor GSK360A enhanced 
al in their capacity to predominantly utilize glycolysis for ATP pro-
duction (34), and that glycolysis enables much more rapid access 
to ATP than other metabolic processes (35), the glycolysis-driven 
augmented function is energetically favorable. The mechanisms 
that drive this glycolytic response and its functional consequenc-
es do, however, require further discussion. The increase in energy 
charge in Phd2-deficient neutrophils suggests that an increased 
demand for and utilization of ATP, as reflected in the enhanced 
chemotactic capacity of these cells, is fully matched by the aug-
mented flux through glycolysis. Interestingly, the increase in gly-
colytic flux occurs in the setting of increased G6P production. We 
observed an increase in both m6 fully labeled and m5–m0 partial-
ly labeled and unlabeled G6P fractions, respectively, following 
culture with U13-C. This identifies first that Phd2-deficient neutro-
phils are capable of increased glucose uptake and utilization where 
glucose is freely available, and second, that neutrophils are capa-
Figure 6. Glycolytic inhibition reverses 
hypoxic neutrophil survival and persistence 
in the setting of systemic hypoxia following 
glycolytic inhibition. (A and B) Apoptosis. 
Human peripheral blood neutrophils were 
cultured ex vivo for 20 hours in the presence 
or absence of dialyzed FBS and glucose-free 
media (A) or 2DG (B) and apoptosis assessed 
by morphology. DFBS-glu, dialyzed fetal 
bovine serum-glucose free media. DFBS-glut, 
dialyzed fetal bovine serum-glutamine free 
media. (C–F) In vivo administration of 2DG. 
WT mice were challenged with nebulized LPS 
(T0) (3 mg). Six hours after installation (T6), 
mice were either maintained in normoxia 
(21% O2) or at 10% O2 over an hour prior to i.p. 
installation at T10 with 2DG (500 mg/kg) or 
PBS vehicle control. Mice were sacrificed at 
24 hours (T24) and BAL total cell counts (C), 
neutrophil differential counts (D), neutrophil 
total counts (E), and neutrophil apoptosis 
counts (F) performed or lungs harvested, 
fixed with 10% buffered formalin, paraf-
fin-embedded, and sections stained with 
H&E (G). Original magnification, ×400. Data 
represent mean ± SEM, n = 5, with signifi-
cance determined by one-way ANOVA.
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nebulized LPS and systemic hypoxia, given we have previously 
described the activation of HIF-1α in neutrophils in this setting (11) 
and would predict this to occur in the setting of suppressed PHD2 
activity. Administration of the glycolytic inhibitor 2DG during the 
resolution phase of the lung injury response completely abrogated 
both hypoxic neutrophil survival and the sustained inflammatory 
response. This observation suggests that the therapeutic targeting 
of neutrophil glycolysis may represent a novel approach to limit-
ing inappropriate or persistent neutrophilic inflammation in situa-
tions where increased HIF-1α activity is observed.
Finally, the broader consequences of long-term non-PHD 
isoform-selective inhibition for outcomes of the innate immune 
response require consideration. Our in vivo data would suggest 
that pan hydroxylase inhibition with molidustat results not only 
in enhanced neutrophil functional responses with increased bas-
al motility and chemotaxis, but also in delayed inflammation res-
olution. This raises important questions as to the consequence 
of unchecked HIF activity in the setting of PHD inactivation and 
lactate-glucose recycling between the muscle and the liver and 
improved survival in an endotoxic shock model (40). Since the 
myeloid cell response to an endotoxin challenge predominates in 
the acute response, this raises important questions as to the poten-
tial for neutrophils to undergo gluconeogenesis and the role of glu-
coneogenesis in the systemic response to infection.
To address whether the exaggerated inflammatory response 
observed in Phd2-deficient mice was modulated by the observed 
increase in glycolytic capacity and amenable to therapeutic 
manipulation in vivo, animals were treated with i.p. 2DG 24 hours 
after challenge with nebulized LPS. Despite the potential global 
consequences for the host of glycolytic inhibition, in vivo block-
ade of glycolysis resulted in abrogation of exaggerated neutro-
phil inflammatory responses and survival in the myeloid-specific 
Phd2-deficient mice. This led us to question whether there were 
other situations in which neutrophils demonstrate suppressed 
PHD activity and in which the innate immune response could be 
modified by inhibiting glycolysis. We used the combination of 
Figure 7. Non-PHD isoform-selective inhibition 
in vivo replicates the Phd2-deficient phenotype 
of augmented neutrophilic inflammation. WT 
mice were treated with the HIF-prolyl hydroxylase 
inhibitor molidustat (5 mg/kg) or vehicle control 
(DMSO) by gavage 2 hours (T–2) prior to challenge 
with nebulized LPS (3 mg) (T0). (A and B) Whole 
blood was harvested at T48 for percentage of 
reticulocyte counts (A) and packed cell volume 
measurements (B). (C and D) Recruitment. Mice 
were sacrificed 6 hours after LPS installation (T6) 
and total cell counts in BAL were determined (C). 
The chemotactic mobility of neutrophils recovered 
from the BAL toward KC was determined ex vivo 
using neuroprobe chambers (D). (E and F) Resolu-
tion. Twenty-four hours after the initial molidustat 
dosing (T22), a second dose of molidustat (5 mg/
kg) was administered by gavage and animals 
sacrificed after a further 22-hour period (T48). BAL 
total cell counts (E) and neutrophil (F) total counts 
were performed. (G and H) Twenty-four hours 
after LPS challenge, mice (T24) were sacrificed and 
bone marrow neutrophils harvested for Seahorse 
quantification of ECARs (basal ECAR levels shown) 
(G). ATP levels were measured in BAL neutrophils 
by LC-MS (H). Data represent mean ± SEM of at 
least 4 independent experiments, with significance 
determined by unpaired t test.
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quots. Hemocytometer counts were performed on the recovered BAL 
samples, which were then pelleted (1000 g, 5 minutes, 4°C) and resus-
pended in FCS prior to cytocentrifugation for differential cell counts 
and morphologic scoring of apoptosis. Chemokine/cytokine concen-
trations in lavage samples were determined by BD cytometric bead 
array using BD FACSArray acquisition software. Limits of detection 
were 10–2500 pg/ml.
DSS-induced acute colitis model
Colitis was induced using a previously described method (44) and 
mice sacrificed at day 6. Sections of intestine were stained with anti-
MPO antibody following deparaffinization, and total neutrophils per 
high-power field (hpf) averaged from 5 fields per section.
Neutrophil isolation and culture
Murine inflammatory BAL neutrophils were isolated 24 hours after 
challenge with LPS (0.3 mg), with peripheral blood neutrophils iso-
lated using negative magnetic selection and bone marrow neutrophils 
isolated by discontinuous Percoll gradients. Cells were cultured for 
5–20 hours in normoxia (19 kPa) or hypoxia (3 kPa) at 5% CO2, as pre-
viously described (11).
Neutrophil functional assays
Chemotaxis. 5 × 104 neutrophils were plated on a semipermeable mem-
brane (ChemoTx Chemotaxis System, pore size 5 μm, Neuroprobe) in 
the presence or absence of KC at T0 and following 6 hours of aging, incu-
bated for 1 hour at 37°C, spun at 300 g for 10 minutes, and hemocytome-
ter counts performed. The number of cells in each well was expressed as 
a percentage of the total number of cells loaded into each well.
Respiratory burst. Neutrophils (1 × 106/ml) were cultured with 
5 μM 2′,7′-dichlorofluorescin diacetate (DCF) for 30 minutes, stimu-
lated for 30 minutes with 10 μM fMLP (Sigma-Aldrich), and FL1 geo-
metric mean fluorescence determined by flow cytometry.
Inner mitochondrial membrane potential. Neutrophils (1 × 106/ml) 
were resuspended in 3 nM TMRM (Life Technologies) dissolved in 1× 
HBSS, with and without 10 μM carbonyl cyanide 3-chlorophenylhy-
drazone (CCCP) (Sigma-Aldrich), and FL2 geometric mean fluores-
cence determined by flow cytometry.
Mitochondrial ROS production. Neutrophils (1 × 106/ml) were 
resuspended in 5 μM MitoSOX (Life Technologies) dissolved in 1× 
DPBS, with and without 10 μM CCCP (Sigma-Aldrich), and FL2 geo-
metric mean fluorescence determined by flow cytometry.
Phagocytosis. 1 × 106 inflammatory BAL neutrophils were incu-
bated with Alexa Fluor 488–conjugated E. coli BioParticles (Thermo 
Fisher Scientific) (MOI 10:1) for 1 hour. Ice controls were included 
to account for bacterial adherence as opposed to internalization. 
Cells were washed with ice-cold PBS, resuspended in FACS buffer, 
and analyzed by flow cytometry. Data analysis was carried out with 
FlowJo version 10.
Flow cytometry
Mouse BAL cells were treated with α-CD16/32 Fc block (eBioscience) 
and mouse serum (Thermo Fisher Scientific) prior to staining with 
antibodies. Relevant full minus one (FMO) samples for each group 
were used as controls. Antibodies used were as follows: Ly6G (1A8, 
BioLegend), CD11a (M17/4, BioLegend), CD11b (M1/70, BioLegend), 
CXCR2 (SA044G4, BioLegend), and CXCR1 (FAB8628A-025, RnD). 
represents an important divergence from the normal physiolog-
ical state in which PHD2 expression follows HIF transcriptional 
activation. Our observation, while providing important supportive 
evidence for the dominance of Phd2 in neutrophils in normoxia, 
also highlights the potential for disordered neutrophil-mediated 
inflammatory responses following treatment with non-PHD iso-
form selective inhibitors and suggests a degree of caution when 
considering the long-term clinical use of pan hydroxylase inhib-
itors (30) in the treatment of chronic anemia. Our data are also 
further demonstration of the need for the development of more 
selective targeting of individual PHD enzymes in the clinical arena.
Methods
Animals
Lysozyme M–driven Cre (LysM-Cre) targeted Phd2 deletions to 
myeloid lineage cells with animals backcrossed to a C57BL/6 back-
ground (10). Phd2fl/fl LysM-Cre–/– littermates were used as WT controls. 
Mice with MRP8-driven Cre-targeted Phd2 deletion (Phd2fl/fl MRP8-
Cre+/–) were generated by crossing Phd2fl/fl animals with the previous-
ly reported neutrophil-specific Cre driver MRP8 (27). For DSS colitis, 
C57BL/6 WT and previously described whole animal heterozygous 
Phd2+/– animals were studied (41). Mice with conditional tamoxi-
fen-induced deletion of Phd2 (Phd2Rosa26CreERT2;fl/fl) were used in the 
study of neutrophil energy states and glycolytic capacity (10). Alveolar 
macrophage depletion was performed using 48 hours pretreatment 
with clodronate, as previously described (25).
Intratracheal pneumonia model
WT C57BL/6 mice were anesthetized with ketamine (100 mg/kg i.p.; 
Vetalar V, Pfizer) and acepromazine (5 mg/kg i.p.; Calmivet Solution 
Injectable, Vetoquinol). The fur was shaved from the neck and a small 
incision made. The trachea was then exposed by blunt dissection and 
cannulated with a 24-gauge cannula (Jelco Radiopaque Cannula, 
Smiths Medical International Ltd.). Each mouse then had 1 × 107 CFU 
of TIGR4 instilled via the trachea. At 14 hours, BAL was performed 
via cannulation of the trachea. Total cell counts were calculated using 
hemocytometer counts and differential counts assessed on cytocentrif-
ugation slides. Levels of IgM were analyzed using commercially avail-
able kits (Mouse IgM ELISA Quantitation Set, Bethyl Laboratories Inc.).
Quantification of viable bacterial counts
Ten-fold serial dilutions were performed on whole blood aliquots. 
Three 10 μl drops from each of 6 dilutions were then plated onto blood 
agar plates and cultured overnight in 37°C to calculate viable bacterial 
counts. After collection of the BAL fluid, the lungs were carefully dis-
sected and stored in sterile tubes. The lungs were homogenized and 
10-fold serial dilutions performed on each sample to calculate viable 
bacterial counts, which were normalized to count per pair of lungs.
LPS acute lung injury model
Direct tracheal instillation of bacterial LPS (0.3 mg) was performed 
on anesthetized mice. For animals receiving treatment with 2DG, 
LPS (3 mg) was administered via nebulization, enabling subsequent 
i.p. administration of either 2DG (500 mg/kg) or PBS vehicle control 
(42). Mice were sacrificed at 6, 24, and 48 hours (43), tracheas recan-
nulated, and lungs instilled with 3.5 ml of ice-cold PBS in 0.5 ml ali-
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Glycolytic flux
Murine BAL leukocytes (0.5 × 106) were incubated for 6 hours in 
RPMI 1640 medium (supplemented with 5.5 mM unlabeled glucose, 
10% FCS, and 1% penicillin/streptomycin) containing 0.4 μCi/ml 
[5-3H]-d-glucose (PerkinElmer). Cells were pelleted (420 g for 10 
minutes) and supernatant transferred into glass vials containing 12% 
perchloric acid sealed with rubber stoppers. 3H2O was captured in 
hanging wells containing a piece of Whatman paper soaked with H2O 
over a period of 48 hours at 37°C to reach saturation. Radioactivity in 
the paper was determined by liquid scintillation counting.
Intracellular glycogen stores
Murine BAL leukocytes (1 × 106/condition) were lysed with 200 μl 
ice-cold H2O and boiled for 10 minutes at 95 degrees; lysates were 
centrifuged at 18,000 g at 4°C for 10 minutes to remove cell debris 
and snap frozen. Glycogen concentration was measured by colori-
metric assay (BioVision).
Energy status
A total of 1 × 106 murine BAL leukocytes were harvested in 100 μl 
of ice-cold 5% PCA supplemented with 1 mM EDTA. ATP, ADP, and 
AMP levels were measured using ion-pair RP-HPLC. The energy 
charge was expressed as ([ATP] + 1/2 [ADP]/[ATP] + [ADP] +[AMP]), 
and the energy status of the cells as the ratio of ATP to ADP content.
LC-MS
Murine BAL leukocytes (2 × 106/condition) were harvested in 100 μl 
of 80% methanol. Measurements of relative levels of analyte abun-
dance and 13C incorporation into glycolytic intermediates were per-
formed using a Dionex UltiMate 3000 LC System (Thermo Scien-
tific) coupled to a Q Exactive Orbitrap Mass Spectrometer (Thermo 
Scientific) operated in negative mode. Practically, 25 μl of sample was 
injected on a SeQuant ZIC/pHILIC Polymeric column (Merck Milli-
pore). The gradient started with 10% solvent B (10 mM NH4-acetate 
in mqH2O, pH 9.3) and 90% solvent A (acetonitrile) and remained 
at 10% B until 2 minutes after injection. Next, a linear gradient to 
80% B was carried out until 29 minutes. At 38 minutes, the gradient 
returned to 40% B, followed by a decrease to 10% B at 42 minutes. 
The chromatography was stopped at 58 minutes. The flow was kept 
constant at 100 μl/min, and the column was kept at 25°C throughout 
the analysis. The MS operated in full scan–SIM mode using a spray 
voltage of 3.2 kV, capillary temperature of 320°C, sheath gas at 10.0, 
auxiliary gas at 5.0. AGC target was set at 1e6 using a resolution of 
140,000, with a maximum IT of 500 ms. Data collection and anal-
ysis were performed using Xcalibur Software (Thermo Scientific). 
Isotope correction was carried out as previously described (45) using 
an in-house software tool.
Reducing equivalents
Ratios of oxidized to reduced NADP/NADPH were calculated in 
murine BAL leukocyte lysates (1 × 106/condition) following quantifica-
tion by fluorimetric enzyme cycling assay (AbCam).
Statistics
Significance was determined by unpaired 2-tailed t tests unless other-
wise stated. Data are expressed as mean ± SEM and are representative of 
at least 3 independent experiments. P < 0.05 was considered significant.
Live cells were gated following staining with DAPI (Invitrogen) prior to 
acquisition. BAL neutrophils were gated according to Ly6G+ and for-
ward scatter (FSC)/side scatter (SSC) properties. Cells were acquired 
on an LSRFortessa (BD). Compensation was performed using BD 
FACSDiva software and data analyzed with FlowJo version 10.
Isolation, culture, and functional assays of BMDM
Red blood cell lysis was carried out on whole bone marrow cells from 
naive WT and Phd2-deficient mice. Cells were cultured in Glutamax 
DMEM supplemented with 1% penicillin/streptomycin, 10% FBS, and 
20% L929 medium. Successful differentiation following 7 days of culture 
was determined by FACS staining for the macrophage marker F4/80.
Phagocytosis. Alexa Fluor 488–conjugated E. coli BioParticles 
(MOI 1:1) were administered to cells for 1 hour. Following vigorous 
washing with PBS, phagocytosis of E. coli was measured using flow 
cytometry. Data analysis was carried out with FlowJo version 10.
Efferocytosis. Differentiated BMDM cells were incubated with 
PKH26-stained apoptotic human neutrophils (cultured for 20 hours 
in normoxic conditions) at a ratio of 5:1 for 1 hour. Following vigorous 
washing with PBS, uptake of apoptotic human neutrophils was assessed 
by flow cytometry. Data analysis was carried out with FlowJo version 10.
RNA isolation and relative quantification
Murine BAL leukocytes (1 × 106/condition) were lysed and RNA 
extracted using the mirVana Total RNA Isolation Protocol (Ambion). 
Samples were treated with DNase (Ambion) and random hexamer 
cDNA synthesized by reverse transcription. Assays-on-Demand Gene 
Expression TaqMan MGB 6FAM dye–labeled products (Applied Bio-
systems) were used for relative quantification of cDNA.
Validation of Phd2 transcript knockdown
For Phd2fl/fl LysM-Cre+/– mice, Percoll-purified bone marrow neutro-
phils from Phd2–/– and WT littermates were FACS sorted based on 
FSC/SSC. For Phd2fl/fl MRP8-Cre+/– mice, following BAL neutrophil 
isolation from mice challenged with nebulized LPS (3 mg) sacrificed 
at 48 hours after challenge, cells were subjected to Percoll density 
centrifugation. Purified cells were lysed, and RNA was extracted and 
reverse transcribed. Assays-on-Demand Gene Expression TaqMan 
MGB 6FAM dye–labeled products (Applied Biosystems) were used 
for relative quantification of cDNA (Phd2 probe: ACGAAAGCCAT-
GGTTGCTTGTTACCCA; forward: GCTGGGCAACTACAGGATA-
AAC; reverse: CATAGCCTGTTCGTTGCCT).
Immunohistochemistry
For histological sections, unlavaged lungs were fixed via the trachea 
with 10% buffered formalin at 20 cm H2O. Paraffin-embedded blocks 
were prepared and sections stained with anti–HIF-1α (polyclonal; 
Novus Biologicals), anti–HIF-2α (clone ep 190b; Novus Biologicals), or 
isotype control following deparaffinization.
Seahorse
Neutrophils were resuspended in XF assay media at a concentration of 
3 × 106/ml. Three million cells per condition were plated onto a XF24 
cell plate precoated with Cell-Tak (Corning). Cells were stimulated with 
fMLP (10 μM) or fMLP plus glucose (1 mg/ml). The oxygen consump-
tion rate (OCR) and ECAR were measured at intervals of 7 minutes over 
a 90-minute cycle using a Seahorse XF24 (Seahorse Bioscience USA).
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